Fletikumab

Fletikumab is an experimental drug that is being studied for its potential use in the treatment of rheumatoid arthritis. It is a human monoclonal antibody that targets the interleukin-6 receptor (IL-6R).

Mechanism of Action

Fletikumab works by binding to the IL-6R and blocking the interaction of IL-6 with its receptor. This prevents the activation of the IL-6 pathway, which is known to play a key role in the inflammatory response associated with rheumatoid arthritis.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of fletikumab in patients with rheumatoid arthritis. These trials have shown promising results, with patients receiving fletikumab showing improvements in symptoms and disease activity compared to those receiving placebo.

Side Effects

Like all drugs, fletikumab can cause side effects. The most common side effects reported in clinical trials include nausea, headache, and injection site reactions. Serious side effects, such as infections, have also been reported.

Future Directions

Further research is needed to fully understand the potential benefits and risks of fletikumab in the treatment of rheumatoid arthritis. Ongoing and future clinical trials will provide more information on the safety and efficacy of this drug.

See Also

• Rheumatoid arthritis
• Interleukin-6
• Clinical trials
• Monoclonal antibodies